pHLIP

Executive Summary

pHLIP, Inc. is a biotechnology company pioneering a proprietary pH-Low Insertion Peptide (pHLIP®) platform for targeted delivery of therapeutics and imaging agents to acidic diseased tissues, including cancer, inflammation, and fibrosis. Founded in 2006 and based in New Haven, Connecticut, the company exploits the metabolic hallmark of high cell surface acidity in diseased cells to achieve precise targeting, potentially improving patient outcomes while minimizing systemic toxicity. The pHLIP platform is versatile, enabling both diagnostic and therapeutic applications across multiple indications. As a private company, pHLIP has advanced its technology through preclinical and early clinical stages, leveraging collaborations and grant funding. The company's focus on the underexploited acidic tumor microenvironment differentiates it from other targeted delivery approaches.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 clinical data readout for lead oncology candidate50% success
• Q4 2026Strategic partnership for pHLIP-based imaging or therapeutic asset40% success
• Q2 2026Series C financing or grant award to fund pipeline advancement70% success